LWAC News and Press, Locust Walk Acquisition Corp. From 07/16/21

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, announced today the publication of data highlighting the role of eukaryotic translation i...

BOSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ: LWAC) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that on May 28, 2021 it received a notice from Nasdaq Regul...

Ali Group ignites a potential bidding war for Welbilt (WBT). Cimarex Energy (XEC) and Cabot Oil & Gas Corporation (COG) combine in an $8.5 billion all-stock deal. United Rentals (UFN) completes the acquisition of General Finance Corporation (GFN) in 40 days. For further ...

SPAC Locust Walk Acquisition Corp. (LWAC) and biopharma eFFECTOR Therapeutics have entered into a definitive merger agreement.The transaction is expected to close in Q3 2021. The combined company will be named eFFECTOR Therapeutics and is expected to be listed on Nasdaq under the ti...

Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical milestones Merger expected to be completed in third quarter of ...